API | intepirdine

intepirdine Report issue

Small molecule Experimental

AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW

Intepirdine (INN; developmental codes SB-742457, RVT-101) is a selective 5-HT6 receptor antagonist with potential cognition, memory, and learning-enhancing effects. It was under development by GlaxoSmithKline for the treatment of Alzheimer's disease and demonstrated some preliminary efficacy in phase II clinical trials. GSK chose not to continue development and sold the rights to Axovant Sciences for $5 million in December 2014. ^Wikipedia

Chemistry

SMILES: O=S(=O)(c1ccccc1)c2cnc3c(cccc3c2)N4CCNCC4
InChIKey: JJZFWROHYSMCMU-UHFFFAOYSA-N
Mol. Mass: 353.45
ALogP: 2.48 Partition coefficient
ChEMBL Molecule:
intepirdine

More Chemistry

Pharmacology

Mechanism of Action:
- 5-hydroxytryptamine receptor 6 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

3-benzenesulfonyl-8-piperazin-1-ylquinoline | gsk742457 | gsk-742457 | intepirdine | rvt-101 | sb742457 | sb 742457 | sb-742457

Organizations (4)

Research & Development (4)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (4)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (4)

Alzheimer Disease (Phase 3)

Lewy Body Disease (Phase 2/Phase 3)

Parkinson Disease (Phase 2)

Pulmonary Arterial Hypertension (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 11
# of Trial Organizations: 4

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue